Brown, Lisle/Cummings’s ARS Pharmaceuticals SPRY Stock Holding History

Brown, Lisle/Cummings’s Portfolio SPRY Stock Details SPRY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$1.72K	Hold	400	–	–	﹤0.01%	881
2026 Q2	$3.2K	Hold	400	–	–	﹤0.01%	770
2026 Q1	$3.21K	Hold	400	–	–	﹤0.01%	738
2025 Q4	$4.66K	Hold	400	–	–	﹤0.01%	562
2025 Q3	$4.02K	Hold	400	–	–	﹤0.01%	589
2025 Q2	$6.98K	Hold	400	–	–	﹤0.01%	539
2025 Q1	$5.03K	Hold	400	–	–	﹤0.01%	555
2024 Q4	$4.22K	Hold	400	–	–	﹤0.01%	548
2024 Q3	$5.8K	Buy	+400	New	+$4.76K	﹤0.01%	504

Other funds holding SPRY

Aberdeen Group Edinburgh, United Kingdom $72.4B AUM 24.61% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return

General American Investors New York $1.71B AUM 30.1% 1-Year Est. Return

Pavaki Capital Management Pueblo, Colorado $294M AUM 34.46% 1-Year Est. Return

Empire Life Investments Toronto, Ontario, Canada $1.83B AUM 33.18% 1-Year Est. Return

CenterBook Partners Greenwich, Connecticut $2.18B AUM 12.5% 1-Year Est. Return

Investment Management Associates Greenwood Village, Colorado $490M AUM 6.7% 1-Year Est. Return

Levin Capital Strategies New York $1.42B AUM 19.05% 1-Year Est. Return

Hennion & Walsh Asset Management Parsippany, New Jersey $3.42B AUM 25.82% 1-Year Est. Return

Bank of New York Mellon New York $608B AUM 32.77% 1-Year Est. Return

Brown, Lisle/Cummings's SPRY Position: Q3 2026 in Review

Brown, Lisle/Cummings held its ARS Pharmaceuticals (SPRY) position steady in Q3 2026 at 400 shares worth $1.72K. The position accounts for ﹤0.01% of the portfolio, ranked #881.

Brown, Lisle/Cummings first reported a position in SPRY in Q3 2024 and has held it in 9 quarters since. The position peaked at $6.98K in Q2 2025. 62 funds tracked by Wall St. Rank hold SPRY as of Q3 2026.

Brown, Lisle/Cummings held 400 shares of ARS Pharmaceuticals worth $1.72K as of Q3 2026.
Brown, Lisle/Cummings left its ARS Pharmaceuticals share count unchanged in Q3 2026.
ARS Pharmaceuticals made up ﹤0.01% of Brown, Lisle/Cummings's portfolio in Q3 2026, its #881 holding.
Brown, Lisle/Cummings first reported a position in ARS Pharmaceuticals in Q3 2024 and has held it in 9 quarters since.
Brown, Lisle/Cummings's ARS Pharmaceuticals position peaked at $6.98K in Q2 2025.
62 funds tracked by Wall St. Rank held ARS Pharmaceuticals as of Q3 2026.

Based on Brown, Lisle/Cummings's 13F filing for Q3 2026, filed 16 Oct 2026.